title: A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting.
authors.forename: C
authors.initials: C
authors.lastname: McAdam-Marx
authors.forename: X
authors.initials: X
authors.lastname: Ye
authors.forename: D I
authors.initials: DI
authors.lastname: Brixner
authors.forename: R
authors.initials: R
authors.lastname: Fabunmi
authors.forename: M
authors.initials: M
authors.lastname: Wintle
authors.forename: K S
authors.initials: KS
authors.lastname: Boye
authors.forename: D
authors.initials: D
authors.lastname: Misurski
authors.forename: L L
authors.initials: LL
authors.lastname: Nielsen
mesh_terms: D001835:Body Weight / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D000077270:Exenatide; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms